UL

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Trovagene closes acquisition of CLIA laboratory assets

Wednesday, February 8, 2012 12:41 PM

Trovagene, a developer of trans-renal molecular diagnostics based in San Diego, Calif., has closed its acquisition of MultiGEN Diagnostics’ clinical laboratory assets. Trovagene previously announced the execution of the asset acquisition agreement on Jan. 6, 2012.

More... »

Perceptive Informatics garners top ratings

Friday, January 20, 2012 03:06 PM

Perceptive Informatics, an eClinical solutions provider and a subsidiary of Parexel International, received top marks for its medical imaging services in an independent survey on the medical imaging market conducted by Blue Pyramid Consulting.

More... »

AMRI announces additional actions to streamline operations

Monday, January 9, 2012 01:40 PM

Albany Molecular Research (AMRI) took steps in the fourth quarter of 2011 to align the business to current and expected market conditions, including reducing the company’s workforce, right size capacity and reduce operating costs for 2012.

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »

Linegen, Fast Forward collaborate to develop gene and biomarker assays for MS

Friday, December 16, 2011 08:04 AM

Lineagen and Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, have formed an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis (MS). The goal of the program is to develop a test that can aid clinicians in diagnosing MS, distinguishing it from other neurological disorders, and providing the prognostic information needed to help guide treatment decisions and response to therapies.

More... »

Cerulean secures $15 million in Series D financing

Thursday, December 15, 2011 03:56 PM

Cerulean Pharma has closed a $15 million Series D financing with participation from new investor, CVF, an affiliate of Henry Crown of Chicago, Illinois, as well as full participation from all other existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. In conjunction with the closing of the financing, Robert Paull, a co-founder and managing partner at Lux Capital, has joined Cerulean's board of directors as the director designated jointly by Lux Capital and CVF.

More... »

Molecular Imaging partners with Dana-Faber Cancer Institute

Thursday, December 15, 2011 08:15 AM

Molecular Imaging has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber. Access to these lines expands Molecular Imaging’s ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma and melanoma.  

More... »

ICON to acquire BeijingWits Medical Consulting

Monday, December 12, 2011 01:21 PM

ICON has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting, a CRO in China. The transaction is expected to close in the first quarter of 2012.

More... »

Molecular Partners expands research collaboration with Janssen Biotech

Thursday, December 8, 2011 12:17 PM

Molecular Partners has entered into a strategic research collaboration and option agreement with Janssen Biotech to research, discover and develop DARPin products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins, to address diseases where continued unmet needs for effective treatment options continue to exist.

More... »